New antiviral agents for the treatment of hepatitis C: ABT-450

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 5, 2014, Pages 711-716

  Carrion, Andres F ^a   Gutierrez, Julio ^a   Martin, Paul ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

ABT 450; Antiviral agents; Hepatitis C; Protease inhibitors; Sustained virological response

Indexed keywords

ABT 072; ABT 267; ABT 333; ABT 450; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BOCEPREVIR; PEGINTERFERON ALPHA2A; RIBAVIRIN; RITONAVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; CLINICAL TRIAL (TOPIC); DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; GENOTYPE; HEPATITIS C; HUMAN; INSOMNIA; NAUSEA; NONHUMAN; PRURITUS; TREATMENT DURATION; VIRUS INFECTION; VOMITING; XEROSIS;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; MACROCYCLIC COMPOUNDS; RIBAVIRIN; RITONAVIR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84896267601     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.889116     Document Type: Article

References (29)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29:S74-81
2. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36:S47-56
3. Kanwal F, Lok AS, El-Serag HB. CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Gastroenterology 2013;144:478-81
4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64
5. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010;51:1122-6
6. Poordad F, Agarwal K, Younes Z, et al. Low relapse rate leads to high concordance of SVR4 and SVR12 with SVR24 after treatment with ABT-450/r, ABT-267, ABT-333 + ribavirin in patients with chronic HCV genotype 1 infection in the AVIATOR study. Hepatology 2013;S1:735A
7. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007;5:453-63
8. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
9. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17
10. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303
11. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
12. Matthews SJ, Lancaster JW. Telaprevir: a hepatitis C NS3/4A protease inhibitor. Clin Ther 2012;34:1857-82
13. Garg V, Van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011;54:20-7
14. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44
15. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55:742-8
16. Manns MP, Von Hahn T. Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov 2013;12:595-610
17. Asselah T. ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection. J Hepatol 2013;59:885-8
18. Lawitz E, Poordad F, DeJesus E, et al. ABT-450/ritonavir (ABT-450/r) combined with pegylated interferon alpha-2a/ribavirin after 3-day monotherapy in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12-week sustained virologic response (SVR12) and safety results. J Hepatol 2012;56:S470
19. Kowdley KV, Lawitz E, Poordad F, et al. Safety and efficacy of interferon-free regimens of ABT-450/R, ABT-267, ABT-333 ± ribavirin in patients with chronic HCV GT1 infection: results from the aviator study. J Hepatol 2012;58:S2
20. Abbvie demonstrates 96 percent SVR(12) in its phase III study of treatmentexperienced patients with genotype 1 hepatitis C. Available from: http://abbvie.mediaroom.com/2013-12-10-AbbVie-Demonstrates-96-percent-SVR-12-in- its-Phase-III-Study-of- Treatment-Experienced-Patients-with-Genotype-1- Hepatitis-C [Last accessed 13 December 2013]
21. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013;368:45-53
22. Lawitz E, Poordad F, Kowdley KV, et al. A phase 2a trial of 12-week interferonfree therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol 2013;59:18-23
23. Lawitz E, Hezode C, Varunok P, et al. Interferon- and ribavirin-free regimen of ABT-450/r + ABT-267 in HCV genotype 1b-infected treatment-na?̈ve patients and prior null responders. Hepatology 2013;S1:62A
24. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87
25. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93
26. Cohen DE, Xie W, Larsen L, et al. Safety of ribavirin-containing regimens of ABT-450/r, ABT-333, and ABT-267 for the treatment of HCV genotype 1 infection and efficacy in subjects with ribavirin dose reductions. Hepatology 2013;S1:140A
27. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9:310-22
28. Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29:687-710
29. Zeng QL, Zhang JY, Zhang Z, et al. Sofosbuvir and ABT-450: terminator of hepatitis C virus? World J Gastroenterol 2013;19:3199-206